Navigation Links
Insmed CEO to Present at Drug Discovery & Development Conference
Date:7/25/2008

CEO Geoffrey Allan Will Discuss Company's IPLEX(TM) Program in Myotonic

Muscular Dystrophy

RICHMOND, Va., July 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM) a developer of follow-on biologics and biopharmaceuticals, today announced that Geoffrey Allan, Ph.D., CEO of Insmed, will present at IBC's 13th Annual Drug Discovery and Development of Innovative Therapeutics on Thursday, August 7th, 2008 at 9:25 AM ET.

Dr. Allan will be participating in the Orphan Diseases track of the conference and his presentation will be entitled, "Myotonic Muscular Dystrophy - A Major Unmet Medical Need." He will present Insmed's progress with its Phase II trial for IPLEX(TM) in Myotonic Muscular Dystrophy. The trial, which has seen strong patient and physician interest, is now fully enrolled. It is a six month, randomized, double-blind, placebo-controlled trial being conducted at 13 research centers across the U.S.

The conference will be held from August 4th to August 7th, 2008, at the World Trade Center Boston and the Seaport Hotel in Boston, MA.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that strategic alternatives may never be consummated, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, our common stock could be delisted from The NASDAQ Capital Market and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD

212-850-5683

brian.ritchie@fd.com

Corporate Communications Contact:

John Procter - Gibraltar Associates

202-879-5808

jprocter@gibraltar-llc.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed to Host Second Quarter 2008 Conference Call
2. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
3. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
4. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
5. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
6. Insmed Announces First Quarter 2008 Financial Results
7. Insmed to Present at CBI Follow-On Biologics Conference
8. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
(Date:2/3/2016)... 3, 2016   ViaCyte, Inc ., a ... pluripotent stem cell-derived islet replacement therapy for the ... today announced that ViaCyte and Janssen Biotech, Inc., ... & Johnson, have agreed to consolidate the assets ... agreement provides ViaCyte with an exclusive license to ...
(Date:2/3/2016)... NEW YORK and HOLLISTON, Mass., Feb. 3, ... (Nasdaq: HART ), a biotechnology company developing ... esophagus, trachea and bronchus, today announced that CEO ... BIO CEO & Investor Conference on ... in New York City . ...
(Date:2/3/2016)... , ... February 03, 2016 , ... ... Linux and Unix visualization solutions today announced the addition of a powerful “Session ... users to see the current state of the remote Linux desktop or other ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
(Date:1/28/2016)... 2016 Synaptics (NASDAQ: SYNA ), a leading developer ... quarter ended December 31, 2015. --> ... 2016 increased 2 percent compared to the comparable quarter last year ... 2016 was $35.0 million, or $0.93 per diluted share. ... the first quarter of fiscal 2016 grew 9 percent over the ...
Breaking Biology News(10 mins):